Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies.

Lawrence F EichenfieldEric L SimpsonKim PappJacek C SzepietowskiAndrew BlauveltLeon KircikJonathan I SilverbergElaine C SiegfriedMichael E KuligowskiMay E VenturanzaHoward KallenderHaobo RenAmy S Paller

Published in: American journal of clinical dermatology (2024)

ClinicalTrials.gov identifiers NCT03745638 (registered 19 November 2018) and NCT03745651 (registered 19 November 2018).

Keyphrases

atopic dermatitis
phase iii
double blind
open label
placebo controlled
phase ii
case control
randomized controlled trial